B7-H1/PD-L1/CD274 Antibody

• Catalog Number: orb1806316
• Category: Antibodies
• Description: Anti-B7-H1 / PD-L1 / CD274 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
• Target: B7-H1 / PD-L1 / CD274
• Clonality: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Human, Monkey, Mouse
• Concentration: Batch dependent
• Buffer/Preservatives: 100 mM Proline/Acetic acid 20mM Arginine pH 5.0
• Purity: >95%
• Purification: Protein A
• UniProt ID: Q9NZQ7
• MW: 145 kDa
• Tested applications: ELISA, FA, FACS, In vivo
• Expression System: CHO
• Endotoxins: <0.001 EU/ug
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)is more than 100% ;determined by SEC-HPLC.

Immobilized human PD L1 His at 2 μg/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab);EC50=0.005894μg/mL.

Human PD-L1 CHO-K cells were stained with Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC263=1.533 nM.

The endocytosis ratio atezolizumab by HCC827 increased with the increase of antibody concentration; and the Internalization Rate (%) reached 60% at antibody concentration of 0.5 nM.

Atezolizumab inhibited the tumor growth of MC38 on C57BL/6N mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 85.2% at 2 mpk at D35.